Methylsulfonylmethane Cancer Research Results

-Generally Recognized as Safe     Possible Interactions: aspirin, warfarin, NSAIDS

-Supplement dosage: 500mg 2-3times/day


-Anti-inflammatory: ↓NF-κB, ↓COX-2 and iNOS
-↓STAT3
-↓Cyclin D1 and CDK4, halting cell cycle progression.
-↓MMP-2, MMP-9, VEGF limiting invasion.

Methylsulfonylmethane (MSM) — a small, naturally occurring organosulfur compound, also called dimethyl sulfone, that is formed in sulfur metabolism and is also a major oxidation product/metabolite of dimethyl sulfoxide (DMSO). It is classified primarily as a dietary supplement/nutraceutical rather than an approved anticancer drug. Standard abbreviations are MSM and DMSO₂. MSM occurs at low levels in foods and biological fluids and is widely used orally for musculoskeletal and inflammatory conditions. Its most reproducible biology is anti-inflammatory and redox-modulating, whereas anticancer effects remain predominantly preclinical and frequently require very high concentrations.

Primary mechanisms (ranked):

1. Suppression of STAT3/STAT5b signaling and associated oncogenic transcription, including IGF-1R, HER2 and VEGF pathways.
2. Suppression of hypoxia-driven HIF-1α signaling, with downstream reduction of glycolytic and metastatic programs including GLUT1, LDHA, PKM2 and VEGF.
3. Induction of cancer-cell growth arrest and apoptosis, including caspase activation and PARP cleavage in susceptible models.
4. Suppression of NF-κB-driven inflammatory signaling and inflammatory mediators including COX-2, iNOS, TNF-α, IL-1β and IL-6.
5. Suppression of NLRP3 inflammasome activation and mitochondrial ROS-dependent inflammatory signaling.
6. Reduction of migration, invasion and angiogenic/metastatic signaling, particularly through STAT/HIF-1α/VEGF-related pathways.
7. Antioxidant/redox-buffering activity in normal or inflammatory tissues, generally reducing excessive ROS rather than acting as a cancer-selective pro-oxidant.

Bioavailability / PK relevance: MSM is orally absorbed and distributes widely into tissues, including the central nervous system. Human serum concentrations increase during repeated oral supplementation, and available data suggest a systemic half-life greater than approximately 12 hours. Common studied oral doses are approximately 1.5–6 g/day. Oral absorption is therefore not the major translational limitation; the main limitation for cancer applications is the very large exposure gap between supplement-level systemic concentrations and the concentrations used in many anticancer experiments.

In-vitro vs systemic exposure relevance: This is a major limitation. Many direct anticancer studies use approximately 100–500 mM MSM; breast-cancer studies commonly used approximately 300 mM and liver-cancer experiments up to 500 mM. Gastrointestinal cancer IC50 values of approximately 22–28 mg/mL correspond to roughly 230–300 mM. These concentrations are orders of magnitude above the low-micromolar endogenous/systemic range and are unlikely to be reproduced by conventional oral supplementation. Consequently, direct cytotoxic anticancer mechanisms should not be assumed to occur at typical human oral doses.

Clinical evidence status: Human evidence exists mainly for osteoarthritis, pain, exercise/inflammation and cosmetic/skin outcomes, including small randomized controlled trials using approximately 3–6 g/day. Cancer evidence is preclinical, consisting of cell culture and animal/xenograft studies; convincing human anticancer efficacy has not been demonstrated. MSM should therefore be categorized as preclinical for cancer rather than as an established oncology adjunct.

Methylsulfonylmethane Cancer Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr

-Anti-inflammatory: ↓TNF-α, IL-1β, IL-6 
-↓ROS, ↑GSH, ↓NO
-may reduce Aβ plaque burden and tau hyperphosphorylation indirectly
-improves memory in rodents

Methylsulfonylmethane and Alzheimer’s disease: MSM has preliminary neuroprotective evidence but no established human Alzheimer’s disease efficacy. In a rat model of BPA plus γ-radiation-induced AD-like neurotoxicity, MSM reduced oxidative stress and neuroinflammation and ameliorated elevations of Aβ42, phosphorylated tau and acetylcholinesterase while modulating TREM2/DAP12/SYK signaling. Because this is an experimentally induced neurotoxicity model rather than spontaneous human AD, these findings should be classified as preclinical and model-dependent. MSM reaches the human brain, supporting biological plausibility for CNS activity, but therapeutic CNS exposure-response relationships remain poorly defined.

Clinical evidence status: Preclinical only for Alzheimer-related outcomes. There are no convincing randomized human trials establishing MSM as an AD treatment.

Methylsulfonylmethane Alzheimer-Relevant Mechanisms

P: 0–30 min    R: 30 min–3 hr    G: >3 hr